← Back to patent-cliff list
Atumelnant
Tier C — Watch / tradeAtumelnant
Crinetics Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MC2R
Indications (approved)：先天性肾上腺增生, Cushing's syndrome, 异位ACTH综合征, Pituitary ACTH hypersecretion
Regional status
US
Phase III
2025-12-11
EU
Phase III
2025-12-11
China
-
Japan
Phase III
2025-12-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atumelnant?
Approved indications include: 先天性肾上腺增生, Cushing's syndrome, 异位ACTH综合征, Pituitary ACTH hypersecretion.
When does the Atumelnant patent expire?
No public expiry year is available for Atumelnant yet; this page updates once verified.
How do I get a quote for Atumelnant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29